Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Veracyte (VCYT)

Veracyte appoints Tom Miller and Brent Shafer to its board of directors

Neutral Impact 2 of 5 leadership Written later

Veracyte's board appointed Tom Miller, Ph.D., and Brent Shafer as directors on September 3, 2024, effective immediately, following a recommendation from the Nominating and Corporate Governance Committee. The filing describes routine board additions with standard director compensation and indemnification terms, and does not disclose any financial results or changes to company operations.

Key points

  • Board appointed Tom Miller, Ph.D., and Brent Shafer as directors on September 3, 2024, effective immediately.
  • Dr. Miller joins the Regulatory and Compliance Committee; Mr. Shafer joins the Compensation Committee.
  • Both directors are eligible for the non-employee director compensation program and signed the company's standard indemnity agreement.
  • Their terms run until the 2025 annual meeting of stockholders or until a successor is elected.

The filing

CompanyVeracyte (VCYT)
Form8-K, current report
Filed with the SECSep 4, 2024, 4:10 PM ET
Accession number0001384101-24-000133

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:54 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 04, 2024.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.